In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates
Joint Authors
Wan, Kanglin
Liu, Haican
Jiang, Yi
Zhao, Xiuqin
Li, Fu
Wan, Li
Xiao, Tongyang
Wang, Ruibai
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-07-02
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Objectives.
Evaluating the activity of nineteen β-lactams in combination with different β-lactamase inhibitors to determine the most potent combination against Mycobacterium tuberculosis (MTB) in vitro.
Methods.
Drug activity was examined by drug susceptibility test with 122 clinical isolates from China.
Mutations of blaC and drug targets ldtMt1, ldtMt2, dacB2, and crfA were analyzed by nucleotide sequencing.
Results.
Tebipenem (TBM) in combination with clavulanate (CLA) exhibited the highest anti-TB activity.
The MIC of β-lactam antibiotics was reduced most evidently in the presence of CLA, compared to avibactam (AVI) and sulbactam (SUB).
Eight polymorphism sites were identified in blaC, which were not associated with β-lactams resistance.
Interestingly, one strain carrying G514A mutation in blaC was highly susceptible to β-lactams regardless of the presence of inhibitors.
The transpeptidase encoding genes, ldtMt1, ldtMt2, and dacB2, harboured three mutations, two mutations, and one mutation, respectively, but no correlation was found between these mutations and drug resistance.
Conclusion.
The activity of β-lactams against MTB and different synergetic effect of β-lactamase inhibitors were indicated.
TBM/CLA exhibited the most activity and has a great prospect in developing novel anti-TB regimen; however, further clinical research is warranted.
Moreover, the resistance to the β-lactam antibiotics might not be conferred by single target mutation in MTB and requires further studies.
American Psychological Association (APA)
Li, Fu& Wan, Li& Xiao, Tongyang& Liu, Haican& Jiang, Yi& Zhao, Xiuqin…[et al.]. 2018. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. BioMed Research International،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1125935
Modern Language Association (MLA)
Li, Fu…[et al.]. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. BioMed Research International No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1125935
American Medical Association (AMA)
Li, Fu& Wan, Li& Xiao, Tongyang& Liu, Haican& Jiang, Yi& Zhao, Xiuqin…[et al.]. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1125935
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1125935